Intech Investment Management LLC Has $7.78 Million Stake in Insmed, Inc. $INSM

Key Points

• Intech Investment Management LLC increased its holdings in Insmed, Inc. by 43.2%, now owning 101,979 shares worth approximately $7.78 million.
• Several institutional investors, including Mercer Global Advisors and Nuveen Asset Management, have also recently increased their stakes in Insmed, showcasing growing interest in the company.
• Despite a 17.3% earnings miss in its recent quarterly report, analysts maintain a positive outlook, with multiple firms raising their price targets on the stock, now averaging $139.86.

Intech Investment Management LLC raised its holdings in Insmed, Inc. (NASDAQ:INSM - Free Report) by 43.2% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 101,979 shares of the biopharmaceutical company's stock after purchasing an additional 30,752 shares during the period. Intech Investment Management LLC owned about 0.06% of Insmed worth $7,780,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in INSM. Bayforest Capital Ltd raised its position in shares of Insmed by 255.0% during the 1st quarter. Bayforest Capital Ltd now owns 7,054 shares of the biopharmaceutical company's stock valued at $538,000 after acquiring an additional 5,067 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Insmed by 10.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 539,484 shares of the biopharmaceutical company's stock valued at $41,157,000 after acquiring an additional 52,637 shares in the last quarter. Woodline Partners LP raised its position in shares of Insmed by 53.3% during the 1st quarter. Woodline Partners LP now owns 248,770 shares of the biopharmaceutical company's stock valued at $18,979,000 after acquiring an additional 86,540 shares in the last quarter. Caxton Associates LLP acquired a new stake in shares of Insmed during the 1st quarter valued at approximately $441,000. Finally, Parkman Healthcare Partners LLC raised its position in shares of Insmed by 6.3% during the 1st quarter. Parkman Healthcare Partners LLC now owns 37,901 shares of the biopharmaceutical company's stock valued at $2,891,000 after acquiring an additional 2,233 shares in the last quarter.

Insmed Stock Performance

INSM traded down $0.55 during midday trading on Wednesday, reaching $144.20. The company's stock had a trading volume of 407,336 shares, compared to its average volume of 2,744,166. Insmed, Inc. has a twelve month low of $60.40 and a twelve month high of $149.08. The stock has a market cap of $30.48 billion, a P/E ratio of -25.25 and a beta of 0.97. The company has a fifty day simple moving average of $121.29 and a 200 day simple moving average of $92.89. The company has a current ratio of 6.68, a quick ratio of 6.33 and a debt-to-equity ratio of 0.45.

Insmed (NASDAQ:INSM - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). The business had revenue of $107.42 million during the quarter, compared to analyst estimates of $104.06 million. Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.Insmed's revenue for the quarter was up 18.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.94) EPS. Insmed has set its FY 2025 guidance at EPS. Research analysts expect that Insmed, Inc. will post -4.56 earnings per share for the current year.

Insider Transactions at Insmed

In other Insmed news, CFO Sara Bonstein sold 58,400 shares of the company's stock in a transaction that occurred on Monday, July 21st. The stock was sold at an average price of $102.67, for a total value of $5,995,928.00. Following the sale, the chief financial officer owned 73,505 shares in the company, valued at $7,546,758.35. This represents a 44.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Orlov S. Nicole Schaeffer sold 76,520 shares of the company's stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $145.45, for a total value of $11,129,834.00. Following the completion of the transaction, the insider directly owned 36,461 shares in the company, valued at $5,303,252.45. The trade was a 67.73% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 335,097 shares of company stock valued at $39,721,648. Insiders own 3.00% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on INSM. Morgan Stanley increased their target price on Insmed from $126.00 to $144.00 and gave the stock an "equal weight" rating in a research report on Thursday, August 21st. William Blair began coverage on Insmed in a research report on Wednesday, August 20th. They issued an "outperform" rating on the stock. Citigroup raised Insmed to a "buy" rating in a research report on Tuesday, June 10th. HC Wainwright increased their price target on Insmed from $90.00 to $120.00 and gave the stock a "buy" rating in a research note on Wednesday, June 11th. Finally, Stifel Nicolaus increased their price target on Insmed from $121.00 to $145.00 and gave the stock a "buy" rating in a research note on Thursday, August 14th. Sixteen research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $139.86.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.